BPG is committed to discovery and dissemination of knowledge
JOURNAL HOME
Number of total visits
2807622
Number of visits today
67
Number of downloads
2059309
MEMBERSHIP
BPG JOURNALS
Cited by in F6Publishing
For: Guo B, Wei J, Wang J, Sun Y, Yuan J, Zhong Z, Meng F. CD44-targeting hydrophobic phosphorylated gemcitabine prodrug nanotherapeutics augment lung cancer therapy. Acta Biomater 2022;145:200-9. [PMID: 35430336 DOI: 10.1016/j.actbio.2022.04.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Gong J, Shi T, Liu J, Pei Z, Liu J, Ren X, Li F, Qiu F. Dual-drug codelivery nanosystems: An emerging approach for overcoming cancer multidrug resistance. Biomed Pharmacother 2023;161:114505. [PMID: 36921532 DOI: 10.1016/j.biopha.2023.114505] [Reference Citation Analysis]
2 Kohon AI, Man K, Mathis K, Webb J, Yang Y, Meckes B. Nanoparticle targeting of mechanically modulated glycocalyx. bioRxiv 2023:2023. [PMID: 36909503 DOI: 10.1101/2023.02.27.529887] [Reference Citation Analysis]
3 Guo B, Qu Y, Sun Y, Zhao S, Yuan J, Zhang P, Zhong Z, Meng F. Co-delivery of gemcitabine and paclitaxel plus NanoCpG empowers chemoimmunotherapy of postoperative "cold" triple-negative breast cancer. Bioact Mater 2023;25:61-72. [PMID: 36733927 DOI: 10.1016/j.bioactmat.2023.01.014] [Reference Citation Analysis]
4 Miao T, Chen F, Du L, Xiao W, Fu J. Signature based on RNA-binding protein-related genes for predicting prognosis and guiding therapy in non-small cell lung cancer. Front Genet 2022;13:930826. [DOI: 10.3389/fgene.2022.930826] [Reference Citation Analysis]
Write to the Help Desk
© 2004-2023 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345